Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial

BACKGROUND: Additional safe and efficacious vaccines are needed to control the COVID-19 pandemic. We aimed to analyse the efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate. METHODS: HERALD is a randomised, observer-blinded, placebo-controlled, phase 2b/3 clinical trial conducted in...

Descripción completa

Detalles Bibliográficos
Autores principales: Kremsner, Peter G, Ahuad Guerrero, Rodolfo Andrés, Arana-Arri, Eunate, Aroca Martinez, Gustavo Jose, Bonten, Marc, Chandler, Reynaldo, Corral, Gonzalo, De Block, Eddie Jan Louis, Ecker, Lucie, Gabor, Julian Justin, Garcia Lopez, Carlos Alberto, Gonzales, Lucy, Granados González, María Angélica, Gorini, Nestor, Grobusch, Martin P, Hrabar, Adrian D, Junker, Helga, Kimura, Alan, Lanata, Claudio F, Lehmann, Clara, Leroux-Roels, Isabel, Mann, Philipp, Martinez-Reséndez, Michel Fernando, Ochoa, Theresa J, Poy, Carlos Alberto, Reyes Fentanes, Maria Jose, Rivera Mejia, Luis Maria, Ruiz Herrera, Vida Veronica, Sáez-Llorens, Xavier, Schönborn-Kellenberger, Oliver, Schunk, Mirjam, Sierra Garcia, Alexandra, Vergara, Itziar, Verstraeten, Thomas, Vico, Marisa, Oostvogels, Lidia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8610426/
https://www.ncbi.nlm.nih.gov/pubmed/34826381
http://dx.doi.org/10.1016/S1473-3099(21)00677-0

Ejemplares similares

Ejemplares similares